Structure of the detoxification catalyst mercuric ion reductase from Bacillus sp. strain RC607

Several hundred million tons of toxic mercurials are dispersed in the biosphere. Microbes can detoxify organo-mercurials and mercury salts through sequential action of two enzymes, organomercury lyase and mercuric ion reductase (MerA). The latter, a homodimer with homology to the FAD-dependent disulphide oxidoreductases, catalyses the reaction NADPH + Hg(II)----NADP+ + H+ + Hg(0), one of the very rare enzymic reactions with metal substrates. Human glutathione reductase serves as a reference molecule for FAD-dependent disulphide reductases and between its primary structure and that of MerA from Tn501 (Pseudomonas), Tn21 (Shigella), p1258 (Staphylococcus) and Bacillus, 25-30% of the residues have been conserved. All MerAs have a C-terminal extension about 15 residues long but have very varied N termini. Although the enzyme from Streptomyces lividans has no addition, from Pseudomonas aeruginosa Tn501 and Bacillus sp. strain RC607 it has one and two copies respectively of a domain of 80-85 residues, highly homologous to MerP, the periplasmic component of proteins encoded by the mer operon. These domains can be proteolytically cleaved off without changing the catalytic efficiency. We report here the crystal structure of MerA from the Gram-positive bacterium Bacillus sp. strain RC607. Analysis of its complexes with nicotinamide dinucleotide substrates and the inhibitor Cd(II) reveals how limited structural changes enable an enzyme to accept as substrate what used to be a dangerous inhibitor. Knowledge of the mode of mercury ligation is a prerequisite for understanding this unique detoxification mechanism.     

Characterization of the rough endoplasmic reticulum ribosome-binding activity.

The rough endoplasmic reticulum membranes of mammalian cells contain specific ribosome-binding sites. A purification to apparent homogeneity of a negatively charged protein (ERp180) of relative molecular mass 180,000 (180 K) was reported which was proposed to function as a rough endoplasmic reticulum ribosome receptor. We report here that ribosome-binding site activity quantitatively solubilized from rough endoplasmic reticulum membranes does not cofractionate with ERp180. By contrast, ribosome-binding site activity fractionates as a much smaller, positively charged protein.     

Cartesian causation: body–body interaction, motion, and eternal truths

There is considerable debate among scholars over whether Descartes allowed for genuine body–body interaction. I begin by considering Michael Della Rocca’s recent claim that Descartes accepted such interaction, and that his doctrine of the creation of the eternal truths indicates how this interaction could be acceptable to him. Though I agree that Descartes was inclined to accept real bodily causes of motion, I differ from Della Rocca in emphasizing that his ontology ultimately does not allow for them. This is not the end of the story however, since two of Descartes’s successors offered incompatible ways of developing his conflicted account of motion. I contrast the occasionalist view of Nicolas Malebranche that changes in motion derive directly from divine volitions with the non-occasionalist claim of Pierre-Sylvain Regis that such changes derive from a nature distinct from God. In light of Della Rocca’s interpretation, it is noteworthy that the issue of eternal truths is relevant to both alternative accounts. Indeed, Regis took the doctrine that such truths are created to provide crucial support for his alternative to an occasionalist account of body–body interaction. What does not help Della Rocca, however, is that Regis’s view of motion requires a fundamental revision of Descartes’s ontology.     

内照射小器官剂量计算中减方差技巧的比较和应用

在用人体模型计算内照射比吸收分数的Monte Carlo模拟中,对小尺寸、远距离器官的计算结果通常精度不够,可信度差,这就要求采用减方差技巧。该文采用一个简单模型比较了直接模拟和区域粒子分裂-轮盘赌、强迫碰撞与DXTRAN球、指向概率强迫碰撞3种减方差技巧的效果。结果表明指向概率强迫碰撞方法能更有效解决此类问题。利用中国人体数学模型,选择一组典型的源靶器官对,计算了一个实例,得到了可信度高的吸收分数值并体现了指向概率强迫碰撞方法的优越性。     

中草药黄蜀葵的研究现状与展望

概述了近年来黄蜀葵生物学特性、栽培试验、化学成分、药理实验及新药开发的研究现状,并分析目前研究中存在的问题及今后的研究开发趋势,展望其可在研究和开发治疗缺血性心脏病和缺血性脑血管病等系列新药中取得重大的突破.